Why Hepion Pharmaceuticals Stock Is Soaring Monday

Hepion Pharmaceuticals Inc HEPA shares are surging Monday morning after the company announced positive results from a Phase 2 trial.

What Happened: Hepion said its recently completed Phase 2 ALTITUDE-NASH met its primary endpoint, demonstrating improved physiologic liver function in subjects with stage 3 or greater fibrosis.

The company also said that all secondary endpoints in the trial were met, which included reductions in liver injury biomarkers and multiple fibrosis-associated biomarkers, as well as enhanced liver fibrosis scores.

"We are thrilled that the ALTITUDE-NASH trial met both its primary efficacy and safety endpoints, in particular with the 225 mg rencofilstat dose showing the greatest benefit to liver function and multiple NASH-associated biomarkers," said Todd Hobbs, chief medical officer of Hepion.

"Our improved understanding of which subjects best respond to rencofilstat can be immediately applied to increase the likelihood of success of our larger and longer ASCEND-NASH paired biopsy trial."

Hepion is a clinical stage biopharmaceutical company focused on artificial Intelligence-assisted therapeutic drug development for the treatment of chronic diseases. The company is expected to report quarterly results at the beginning of June, but a date has not yet been confirmed.

See Also: Nasdaq Futures Rattled By Meta's $1.3B Fine, China's Micron Ban — But Analyst Sees Quick S&P 500 Rally To August Highs

HEPA Price Action: Hepion shares were up 65.9% at $14.72 at the time of publication, according to Benzinga Pro.

Photo: Narupon Promvichai from Pixabay.